1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Equipment & Services
Diamond Biotechnology Co., Ltd

Diamond Biotechnology Co., Ltd

6815.TWO
Diamond Biotechnology Co., LtdTW flagTaipei Exchange
26.90
TWD
-0.15
- -
903.37MMarket Cap
Diamond Biotechnology Co., Ltd
6815.TWO
(Taipei Exchange)

Recent

price

26.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
9.06
9.33
8.87
8.61
10.75
11.83
16.79
19.88
- -
Revenue per Share
1.99
1.69
1.46
0.31
1.14
0.91
1.27
1.89
- -
Basic EPS, GAAP
-2.9
0.87
0.15
0.4
-0.52
2.3
-4.24
0.24
- -
Free Cash Flow per Basic Share
0.11
0.5
1.2
0.82
0.03
0.1
0.08
0.13
- -
Dividend per Share
5.69
5.97
8
6.16
7.05
7.74
8.85
10.72
- -
Book Value per Share
5.99
6.62
7.35
5.86
6.93
7.89
9.23
16.03
- -
Tangible Book Value per Share
21
24
30
36
37
37
37
39
- -
Basic Weighted Avg Shares
193
227
268
306
395
435
616
768
501
Sales/Revenue/Turnover
28.23
24.68
21.39
4.37
12.17
10.82
10.61
14.68
-14.79
Operating Margin (%)
16
20
32
55
58
53
50
28
29
Depreciation Expense
42
41
44
11
42
33
47
73
-70
Net Income, GAAP
18.36
21.68
21.86
18.19
19.46
20.17
19.87
23.5
- -
Effective Tax Rate (%)
21.94
18.09
16.46
3.61
10.61
7.68
7.59
9.53
-14.02
Profit Margin (%)
65
95
124
114
155
67
132
479
347
Working Capital
24
22
96
74
67
25
186
222
174
LT Debt
164
193
250
232
273
303
346
623
542
Total Equity
- -
19.58
13.97
2.76
9.08
7.51
8.4
10.72
- -
Return on Invested Capital (%)
- -
24.16
15.73
3.42
10.81
7.75
8.97
11.75
- -
Return on Capital (%)
- -
30.83
22.83
4.79
17.53
12.29
15.35
19.81
-18.9
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
21.94%
-13.04%
Free Cash Flow
- -
-260.04%
-135.36%
Net Income, GAAP
- -
31.92%
-196.06%
Sales/Revenue/Turnover
- -
14.14%
-34.72%
Total Cash Common Dividend
- -
52.52%
32.69%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
616
2024
- -
- -
- -
- -
768
2025
- -
- -
- -
- -
501

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.27
2024
- -
- -
- -
- -
1.89
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.08
2024
- -
- -
- -
- -
0.13
2025
- -
- -
- -
- -
- -
Similar Companies
Alpha Tau Medical Ltd (DRTS)
Cambria Automobiles plc (CAMB.L)
Omnicell, Inc. (OMCL)
MaxWin International Holdings Limited (8513.HK)
Hologic Inc (HO1.DE)
Standard BioTools Inc. (LAB)
Business
Diamond Biotechnology Co., Ltd researches, develops, manufactures and sells medical equipment and skincare products primarily in Taiwan and internationally. The company offers skincare products under the Timera and Diamond Beauty brands, including facial masks, lotions, creams and essences for skin care and cleaning; medical equipment such as wires, sonic wave devices, radio wave equipment, frozen fat reduction systems and micro plastic surgery consumables including botulinum and collagen injections for wrinkle and sagging improvement; leasing services for medical equipment; and medical beauty management consulting. Founded in 2014 and headquartered at 14F, No. 95, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City, Taiwan, it targets hospitals, clinics and open channels in the biotechnology and medical care industry. In March 2025, the company launched Ronkyla chin filler injection featuring MIT technology in partnership with Tai Zhong to target the NT$7 billion lipolysis market. It listed on the Taipei Exchange in January 2021 under ticker 6815.TWO with paid-in capital of NT$247.8 million.